Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Immunotherapy for pediatric brain tumors: past and present.

Foster JB, Madsen PJ, Hegde M, Ahmed N, Cole KA, Maris JM, Resnick AC, Storm PB, Waanders AJ.

Neuro Oncol. 2019 Oct 9;21(10):1226-1238. doi: 10.1093/neuonc/noz077.

PMID:
31504801
2.

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2016 Nov 15;14(1):313.

3.

Immune-checkpoint blockade and active immunotherapy for glioma.

Ahn BJ, Pollack IF, Okada H.

Cancers (Basel). 2013 Nov 1;5(4):1379-412. doi: 10.3390/cancers5041379.

4.

Immunotherapy of Primary Brain Tumors: Facts and Hopes.

Buerki RA, Chheda ZS, Okada H.

Clin Cancer Res. 2018 Nov 1;24(21):5198-5205. doi: 10.1158/1078-0432.CCR-17-2769. Epub 2018 Jun 5. Review.

5.

Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma.

Sadozai H, Gruber T, Hunger RE, Schenk M.

Front Immunol. 2017 Dec 8;8:1617. doi: 10.3389/fimmu.2017.01617. eCollection 2017. Review.

6.

New developments in immunotherapy for pediatric solid tumors.

Schultz LM, Majzner R, Davis KL, Mackall C.

Curr Opin Pediatr. 2018 Feb;30(1):30-39. doi: 10.1097/MOP.0000000000000564. Review.

PMID:
29189429
7.

Immunotherapy for Pediatric Brain Tumors.

Sayour EJ, Mitchell DA.

Brain Sci. 2017 Oct 21;7(10). pii: E137. doi: 10.3390/brainsci7100137. Review.

8.

Emerging immunotherapies for glioblastoma.

Desai R, Suryadevara CM, Batich KA, Farber SH, Sanchez-Perez L, Sampson JH.

Expert Opin Emerg Drugs. 2016 Jun;21(2):133-45. doi: 10.1080/14728214.2016.1186643. Review.

9.

Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.

Ă–zdemir BC, Siefker-Radtke AO, Campbell MT, Subudhi SK.

Eur Urol Focus. 2018 Apr;4(3):442-454. doi: 10.1016/j.euf.2017.10.001. Epub 2017 Oct 19. Review.

PMID:
29056275
10.

Recent advances and future of immunotherapy for glioblastoma.

Kamran N, Calinescu A, Candolfi M, Chandran M, Mineharu Y, Asad AS, Koschmann C, Nunez FJ, Lowenstein PR, Castro MG.

Expert Opin Biol Ther. 2016 Oct;16(10):1245-64. doi: 10.1080/14712598.2016.1212012. Epub 2016 Jul 27. Review.

11.

Advances in immunotherapy delivery from implantable and injectable biomaterials.

Leach DG, Young S, Hartgerink JD.

Acta Biomater. 2019 Apr 1;88:15-31. doi: 10.1016/j.actbio.2019.02.016. Epub 2019 Feb 13. Review.

12.

Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.

Kato D, Yaguchi T, Iwata T, Morii K, Nakagawa T, Nishimura R, Kawakami Y.

Nihon Rinsho Meneki Gakkai Kaishi. 2017;40(1):68-77. doi: 10.2177/jsci.40.68. Review.

13.

Emerging Nano-/Microapproaches for Cancer Immunotherapy.

Mi Y, Hagan CT 4th, Vincent BG, Wang AZ.

Adv Sci (Weinh). 2019 Jan 13;6(6):1801847. doi: 10.1002/advs.201801847. eCollection 2019 Mar 20. Review.

14.

Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment.

Siu EH, Chan AW, Chong CC, Chan SL, Lo KW, Cheung ST.

Transl Gastroenterol Hepatol. 2018 Nov 7;3:89. doi: 10.21037/tgh.2018.10.16. eCollection 2018. Review.

15.

Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.

Nathenson MJ, Conley AP, Sausville E.

Oncologist. 2018 Jan;23(1):71-83. doi: 10.1634/theoncologist.2016-0025. Epub 2017 Sep 21. Review.

16.

Pediatric Cancer Immunotherapy: Opportunities and Challenges.

Wedekind MF, Denton NL, Chen CY, Cripe TP.

Paediatr Drugs. 2018 Oct;20(5):395-408. doi: 10.1007/s40272-018-0297-x. Review.

17.

From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?

Madden DL.

Curr Oncol Rep. 2018 Feb 7;20(1):8. doi: 10.1007/s11912-018-0662-5. Review.

PMID:
29411148
18.

Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.

Jia H, Truica CI, Wang B, Wang Y, Ren X, Harvey HA, Song J, Yang JM.

Drug Resist Updat. 2017 May;32:1-15. doi: 10.1016/j.drup.2017.07.002. Epub 2017 Aug 19. Review.

PMID:
29145974
19.

Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy.

Ring EK, Markert JM, Gillespie GY, Friedman GK.

Clin Cancer Res. 2017 Jan 15;23(2):342-350. doi: 10.1158/1078-0432.CCR-16-1829. Epub 2016 Nov 10. Review.

20.

Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.

Podar K, Jager D.

Curr Cancer Drug Targets. 2017;17(9):782-805. doi: 10.2174/1568009617666170214103834. Review.

PMID:
28201977

Supplemental Content

Support Center